(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
24 March 2005 (24.03.2005)

PCT

(10) International Publication Number
WO 2005/025563 A1

(51) International Patent Classification[7]: A61K 31/197, 31/195, 31/135, 31/137, 31/5375, 45/06, A61P 25/22, 25/24

(21) International Application Number:
PCT/IB2004/002818

(22) International Filing Date: 30 August 2004 (30.08.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/502,304 12 September 2003 (12.09.2003) US

(71) Applicant *(for all designated States except US)*: **WARNER-LAMBERT COMPANY LLC** [US/US]; 201 Tabor Road, Morris Plains, NJ 07950 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **ARNERIC, Stephen, Peter** [US/US]; Pfizer Global Research and Development, 2800 Plymouth Road, Ann Arbor, MI 48105 (US). **CLARY, Cathryn, Montgomery** [US/US]; Pfizer Inc., 235 East 42nd Street, New York, NY 10017 (US). **FELTNER, Douglas, Eric** [US/US]; Pfizer Global Research and Development, 2800 Plymouth Road, Ann Arbor, MI 48105 (US). **HARRISON, Wilma, Marcia** [US/US]; 7 Century Trail, Harrison, NY 10528 (US). **KAVOUSSI, Richard, James** [US/US]; Pfizer Global Research and Development, 2800 Plymouth Road, Ann Arbor, MI 48105 (US). **PANDE, Atul, Chandra** [US/US]; Pfizer Global Research and Development, 2800 Plymouth Road, Ann Arbor, MI 48105 (US). **TAYLOR, Charles, Price, Jr.** [US/US]; Pfizer Global Research and Development, 2800 Plymouth Road, Ann Arbor, MI 48105 (US).

(74) Agent: **FULLER, Grover, F., Jr.**; Pfizer Inc., 201 Tabor Road, Morris Plains, NJ 07950 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 2005/025563 A1

(54) Title: COMBINATION COMPRISING AN ALPHA-2-DELTA LIGAND AND AN SSRI AND/OR SNRI FOR TREATMENT OF DEPRESSION AND ANXIETY DISORDERS

(57) Abstract: A method is provided of treating depression in mammals, including a human, as well as depression and a concomitant disease, disorder or condition exemplified by, but not limited to, anxiety, sleep disorder and post-traumatic stress disorder. The method comprises administering to the mammal in effective amount a combination of active ingredients comprising a) an alpha-2delta (A2D) ligand or a prodrug thereof, or a pharmaceutically acceptable salt of said 2D ligand or said prodrug and, active agents selected from; (b) a selective serotonin re-uptake inhibitor (SSRI) or a prodrug thereof or a pharmaceutically acceptable salt of said SSRI or said prodrug, (c) a selective noradrenaline re-uptake inhibitor (SNRI) or a prodrug thereof or a pharmaceutically acceptable salt of said NRI or said prodrug and mixtures of (b) and (c). A pharmaceutical composition comprising a therapeutically effective amount (a) an A2D ligand or a pro g thereof, or a pharmaceutically acceptable salt of said A2D ligand or said prodrug and active agents selected from; (b) an SSRI or a prodrug thereof or a pharmaceutically acceptable salt of said SSRI or said prodrug, (c) an SNR or a prodrug thereof or a pharmaceutically acceptable salt of said SNRI or said is prodrug and mixtures of (b) and (c) is also provided. Preferred active ingredients for the treatment and the pharmaceutical composition include pregabalin, gabapentin, sertraline and reboxetine.